These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 26242311)

  • 41. Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases.
    Hansen ME; Mangusan R; Lurain K; Odeny T; George J; Lu C; Manion M; Widell A; Ekwede I; Whitby D; Gulley JL; Kadri SS; Elinoff JM; Barochia A; Torabi-Parizi P; Uldrick TS; Yarchoan R; Ramaswami R
    AIDS; 2022 Nov; 36(14):1969-1978. PubMed ID: 35848586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana.
    Cox CM; El-Mallawany NK; Kabue M; Kovarik C; Schutze GE; Kazembe PN; Mehta PS
    Pediatr Blood Cancer; 2013 Aug; 60(8):1274-80. PubMed ID: 23487320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study.
    Westmoreland KD; Stanley CC; Montgomery ND; Kaimila B; Kasonkanji E; El-Mallawany NK; Wasswa P; Mtete I; Butia M; Itimu S; Chasela M; Mtunda M; Chikasema M; Makwakwa V; Kampani C; Dhungel BM; Sanders MK; Krysiak R; Tomoka T; Liomba NG; Dittmer DP; Fedoriw Y; Gopal S
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27781380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and associated risk factors for Kaposi's sarcoma among HIV-positive patients in a referral hospital in Northern Tanzania: a retrospective hospital-based study.
    Semango GP; Charles RM; Swai CI; Mremi A; Amsi P; Sonda T; Shao ER; Mavura DR; Joosten LAB; Sauli E; Nyindo M
    BMC Cancer; 2018 Dec; 18(1):1258. PubMed ID: 30558571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection.
    Pinzone MR; Berretta M; Cacopardo B; Nunnari G
    Semin Oncol; 2015 Apr; 42(2):258-71. PubMed ID: 25843730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions.
    El-Mallawany NK; Mehta PS; Kamiyango W; Villiera J; Peckham-Gregory EC; Kampani C; Krysiak R; Sanders MK; Caro-Vegas C; Eason AB; Ahmed S; Schutze GE; Martin SC; Kazembe PN; Scheurer ME; Dittmer DP
    Int J Cancer; 2019 Jan; 144(1):110-116. PubMed ID: 30204240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant Kaposi sarcoma and multicentric Castleman's disease in a heart transplant recipient.
    Patel A; Bishburg E; Zucker M; Tsang P; Nagarakanti S; Sabnani I
    Heart Lung; 2014; 43(6):506-9. PubMed ID: 25169666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kaposi sarcoma-associated herpesvirus in non-Hodgkin lymphoma and reactive lymphadenopathy in Uganda.
    Engels EA; Mbulaiteye SM; Othieno E; Gomez M; Mathew S; Cesarman E; Knowles DM; Chadburn A
    Hum Pathol; 2007 Feb; 38(2):308-14. PubMed ID: 17097130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
    Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
    Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?
    Alkaied H; Harris K; Elsayegh D; Khachaturova I; Awasum M; Varma S
    Med Oncol; 2012 Jun; 29(2):1109-13. PubMed ID: 21472488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kaposi sarcoma-associated herpesvirus, HIV-1 and Kaposi sarcoma risk in black South Africans diagnosed with cancer during antiretroviral treatment rollout.
    Motlhale M; Muchengeti M; Bradshaw D; Chen WC; Singini MG; de Villiers CB; Lewis CM; Bender N; Mathew CG; Newton R; Waterboer T; Singh E; Sitas F
    Int J Cancer; 2023 May; 152(10):2081-2089. PubMed ID: 36727526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kaposi sarcoma herpesvirus-associated cancers and related diseases.
    Goncalves PH; Ziegelbauer J; Uldrick TS; Yarchoan R
    Curr Opin HIV AIDS; 2017 Jan; 12(1):47-56. PubMed ID: 27662501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.
    Min J; Katzenstein DA
    AIDS Res Hum Retroviruses; 1999 Jan; 15(1):51-5. PubMed ID: 10024052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.
    Rasmussen C; Gérard L; Fadlallah J; Corvilain E; Galicier L; Meignin V; Oksenhendler E; Boutboul D
    Blood Adv; 2023 Sep; 7(18):5663-5669. PubMed ID: 37288720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
    Deloose ST; Smit LA; Pals FT; Kersten MJ; van Noesel CJ; Pals ST
    Leukemia; 2005 May; 19(5):851-5. PubMed ID: 15744337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of multicentric Castleman’s disease in HIV-1 infected and uninfected patients: a systematic review.
    Rokx C; Rijnders BJ; van Laar JA
    Neth J Med; 2015 Jun; 73(5):202-10. PubMed ID: 26087799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
    Uldrick TS; Polizzotto MN; Aleman K; O'Mahony D; Wyvill KM; Wang V; Marshall V; Pittaluga S; Steinberg SM; Tosato G; Whitby D; Little RF; Yarchoan R
    Blood; 2011 Jun; 117(26):6977-86. PubMed ID: 21487108
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease.
    El-Mallawany NK; Villiera J; Kamiyango W; Peckham-Gregory EC; Scheurer ME; Allen CE; McAtee CL; Legarreta A; Dittmer DP; Kovarik CL; Chiao EY; Martin SC; Ozuah NW; Mehta PS; Kazembe PN
    Infect Agent Cancer; 2018; 13():33. PubMed ID: 30455728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.
    Polizzotto MN; Uldrick TS; Hu D; Yarchoan R
    Front Microbiol; 2012; 3():73. PubMed ID: 22403576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.